STOCK TITAN
  1. Home
  2. News
  3. XBIO

Xenetic Biosciences Inc - XBIO STOCK NEWS

Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.

Xenetic Biosciences Inc (NASDAQ: XBIO) is a clinical-stage biopharmaceutical leader advancing novel immuno-oncology therapies through its DNase platform and polyxen™ technology. This page provides investors and researchers with centralized access to the company’s latest developments in cancer treatment innovation.

Find timely updates on XBIO’s clinical trial progress, strategic collaborations, and regulatory milestones. Our curated collection includes press releases about orphan-designated therapies, CAR T platform advancements, and preclinical research insights – all essential for tracking the company’s contributions to targeted cancer treatments.

Key updates cover three focus areas: clinical developments in hard-to-treat cancers, technology partnerships enhancing therapeutic efficacy, and scientific publications validating novel approaches to tumor microenvironment modulation. Bookmark this page to stay informed about Xenetic’s progress in developing next-generation biologics and combination therapies.

News

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Rhea-AI Summary
Xenetic Biosciences, Inc. (NASDAQ:XBIO) has entered into agreements with the University of Virginia to advance the development of its systemic DNase program targeting neutrophil extracellular traps. The company has an option to acquire an exclusive license to any new intellectual property arising from the DNase research program. The research is overseen by Dr. Allan Tsung, who is internationally recognized for leading substantial research on the role of NETs in tumor growth, metastasis, and resistance to existing cancer therapies. Xenetic is working towards its first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
none
-
News

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Xenetic Biosciences, Inc. (NASDAQ: XBIO) reported encouraging preclinical data guiding the pathway to the first in human trial for their DNase-based oncology platform. They are driving development towards a Phase 1 program for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. The company also continued partnering discussions to advance the development of systemic DNase and DNase-Armored CAR T programs, ending the quarter with $9.8 million of cash to fund operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
earnings
-
News

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

Rhea-AI Summary
Xenetic Biosciences CEO to participate in Virtual Investor Ask the CEO Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.75%
Tags
conferences
News

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
Xenetic Biosciences to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
conferences
-
News

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Xenetic Biosciences, Inc. (NASDAQ:XBIO) reported its financial results for the second quarter of 2023, highlighting the progress made in advancing its DNase-based oncology platform towards Phase 1 clinical development. The company executed the first Collaborator Statement of Work as part of a collaboration agreement with VolitionRx and CLS Therapeutics, along with continued participation in conferences and investor-focused events. Financially, the company reported a net loss of approximately $1.1 million for the quarter ended June 30, 2023, with a decrease in research & development expenses and an increase in royalty payments from its sublicense with Takeda Pharmaceuticals Co. Ltd. The company ended the quarter with approximately $10.7 million of cash and no debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
earnings
-
News

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
conferences
News

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

Rhea-AI Summary
Xenetic Biosciences, Inc. announces a one-for-ten reverse stock split of its common stock, effective May 15, 2023. Fractional shares will be rounded up to the nearest whole share. Stockholders do not need to send in their current stock certificates. Common stock will trade on the Nasdaq Capital Market under the symbol 'XBIO' and new CUSIP number 984015 602.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.5%
Tags
none
-
News

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.5%
Tags
earnings
-
News

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development

Rhea-AI Summary
Xenetic Biosciences engages Dr. Reid P. Bissonnette as executive consultant for translational research and development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
management
News

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
management
Stock XBIO logo
Xenetic Biosciences Inc

Nasdaq:XBIO

XBIO Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

XBIO Stock Data

3.75M
1.25M
19.06%
6.44%
0.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
FRAMINGHAM